The opioid epidemic has taken countless lives and shows no signs of abating. Solving a problem this dangerous and intractable will require innovative approaches. Tris Pharma has taken up that challenge.
The Monmouth Junction-based drugmaker is developing a treatment for chronic pain that offers relief without the addictive properties of opioids. Success in this endeavor offers a path toward ending the crisis.
In this edition of NJBIZ Conversations, Tris Pharma’s founder and CEO, Ketan Mehta, talks about the work on the pain treatment, other promising products in the pipeline and why New Jersey is a great place for pharmaceutical companies to do business.
NJBIZ Conversations is now available as a podcast, as well as a video. Subscribe to NJBIZ Conversations on Apple or Google Podcasts. Find direct links here: njbiz.podbean.com